FormulaFolio Investments LLC Acquires Shares of 3,440 Zoetis Inc. (NYSE:ZTS)
FormulaFolio Investments LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,440 shares of the company’s stock, valued at approximately $569,000.
Several other hedge funds have also recently made changes to their positions in ZTS. Jeppson Wealth Management LLC purchased a new stake in shares of Zoetis in the third quarter valued at about $25,000. Graves Light Private Wealth Management Inc. purchased a new stake in shares of Zoetis in the fourth quarter valued at about $31,000. Arlington Partners LLC purchased a new stake in Zoetis during the fourth quarter worth about $32,000. Hoover Financial Advisors Inc. purchased a new stake in Zoetis during the fourth quarter worth about $32,000. Finally, Annapolis Financial Services LLC purchased a new stake in Zoetis during the fourth quarter worth about $33,000. Institutional investors own 92.50% of the company’s stock.
In related news, Director Robert W. Scully acquired 7,590 shares of Zoetis stock in a transaction on Friday, February 19th. The shares were acquired at an average cost of $164.68 per share, with a total value of $1,249,921.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Robert Edward Kelly sold 2,055 shares of the business’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $158.05, for a total transaction of $324,792.75. 0.17% of the stock is currently owned by insiders.
ZTS stock opened at $157.88 on Thursday. The company has a market capitalization of $75.02 billion, a PE ratio of 46.85, a price-to-earnings-growth ratio of 4.35 and a beta of 0.71. Zoetis Inc. has a one year low of $121.50 and a one year high of $176.64. The company’s 50 day moving average price is $155.41 and its two-hundred day moving average price is $160.68. The company has a debt-to-equity ratio of 2.41, a quick ratio of 2.60 and a current ratio of 3.47.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 16th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.86 by $0.05. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.73 billion. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. During the same period in the previous year, the firm earned $0.92 earnings per share. On average, research analysts predict that Zoetis Inc. will post 3.63 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 1st. Shareholders of record on Wednesday, April 21st will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date is Tuesday, April 20th. Zoetis’s payout ratio is currently 27.47%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Market Capitalization – What it Means for Investors
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.